Table 3.

Associations of EFS with Patient and Tumor Characteristics in Univariate and Multivariate Cox Proportional Hazards Regression Analyses

Characteristics	Univariate Analysis			Multivariate Analysis
	Hazard Ratio	95% CI	P value	Hazard Ratio	95% CI	P value
Age, years (≤50 vs >50)	0.72	0.40–1.31	0.287	0.66	0.26–1.67	0.380
Menopausal status (pre vs post)	0.87	0.48–1.57	0.632	1.10	0.43–2.84	0.841
Clinical tumor size (T1–2 vs T3–4)	0.70	0.35–1.37	0.294	0.66	0.28–1.52	0.328
Clinical nodal status (N0 vs N+)	0.69	0.39–1.23	0.205	0.45	0.17–1.22	0.117
Histology (ductal vs other)	0.87	0.12–6.39	0.891	1.23	0.16–9.74	0.842
Histological grade (3 vs 1–2)	1.00	0.55–1.83	0.992	1.15	0.60–2.19	0.670
Ki67 score (>35% vs ≤35%)	0.99	0.56–1.75	0.975	0.88	0.47–1.66	0.689
HR status (negative vs positive)	1.06	0.58–1.93	0.855	0.74	0.15–3.70	0.713
Trastuzumab (with vs without)	0.97	0.55–1.73	0.916	0.79	0.43–1.43	0.431
Pathological response (pCR vs non-pCR)	0.35	0.14–0.89	0.028	0.26	0.09–0.74	0.012
Neoadjuvant chemotherapy (combined vs sequential)	1.06	0.60–1.86	0.851	0.97	0.51–1.86	0.930
Adjuvant radiotherapy (yes vs no)	1.23	0.65–2.32	0.531	0.68	0.23-2.06	0.498
Adjuvant endocrine therapy (yes vs no)	0.89	0.49–1.60	0.692	0.45	0.09–2.18	0.318

Abbreviations: CI, confidence interval; EFS, event-free survival; HR, hormone receptor; pCR, pathological complete response.